TransEnterix, the first real competitor to have emerged to Intuitive Surgical in the assisted surgical robotics field, just won FDA clearance for new indications for its Senhance System. Specifically, laparoscopic inguinal hernia repair and laparoscopic cholecystectomy (gallbladder removal) procedures can now be performed with the Senhance.
The Senhance is already cleared for colorectal and gynecologic procedures, but considering the frequency of inguinal hernia repairs and laparoscopic cholecystectomies, the new clearance effectively doubles the number of cases that the system can be used on.
“We have utilized Senhance broadly across a wide range of general surgery, upper GI surgery and colorectal procedures at our institution,” said Professor Dr. Frank Willeke, Chief of Surgery at St. Marien Hospital in Siegen, Germany. “We believe this procedural expansion for the US will allow surgeons there to incorporate the Senhance, as we have, as a highly-efficient, enabling and very promising technology that can impact the vast majority of surgeries commonly performed by general surgeons and their sub-specialties.”
Here’s a video presenting the Senhance system:
Flashbacks: The Coming Future of Surgical Robotics: Interview with CEO of TransEnterix…; TransEnterix Gets FDA Clearance for Senhance Surgical Robot…; Robotic-Assisted Surgery – Current Challenges and Future Directions: Interview with Dr. Mona Orady…
Product page: Senhance Surgical System…